Uncategorized
Lilly reneges on remainder of Rigel deal in another blow for RIPK1 inhibitors
Just a few months after ripping up the central nervous system-focused portion of its RIPK1 deal with Rigel Pharmaceuticals, Eli Lilly has now thrown out the rest of the pact, too.